{"id":"rhpth-1-84","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypercalcemia"},{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL2108078","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"rhPTH (1-84) is the full-length recombinant parathyroid hormone that activates PTH1 receptors on osteoblasts and osteocytes, promoting bone anabolism and increasing bone mineral density. It also enhances renal reabsorption of calcium and stimulates phosphate excretion, thereby normalizing mineral homeostasis. This mechanism makes it effective for treating hypoparathyroidism by replacing deficient endogenous PTH.","oneSentence":"rhPTH (1-84) is a recombinant human parathyroid hormone that binds to PTH1 receptors on bone cells to stimulate bone formation and increase serum calcium and phosphate levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:04:54.768Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypoparathyroidism"}]},"trialDetails":[{"nctId":"NCT07299838","phase":"","title":"Palopegteriparatide in Chronic Hypoparathyroidism","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2024-06-01","conditions":"Hypoparathyroidism","enrollment":90},{"nctId":"NCT01922440","phase":"","title":"A Registry for Participants With Chronic Hypoparathyroidism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2013-07-30","conditions":"Hypoparathyroidism","enrollment":1339},{"nctId":"NCT01199614","phase":"PHASE3","title":"HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism","status":"COMPLETED","sponsor":"Columbia University","startDate":"2009-12","conditions":"Hypoparathyroidism","enrollment":62},{"nctId":"NCT05137730","phase":"PHASE1","title":"A Study of Relative Bioavailability of a New Formulation Compared With the Approved Formulation of rhPTH [1-84] and to Find Out Dose Linearity of the New Formulation in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-11-29","conditions":"Healthy Volunteers","enrollment":96},{"nctId":"NCT03324880","phase":"PHASE4","title":"A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)","status":"COMPLETED","sponsor":"Shire","startDate":"2018-01-24","conditions":"Hypoparathyroidism","enrollment":93},{"nctId":"NCT03878953","phase":"PHASE3","title":"A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism","status":"WITHDRAWN","sponsor":"Shire","startDate":"2022-08-31","conditions":"Chronic Hypoparathyroidism","enrollment":""},{"nctId":"NCT03364738","phase":"PHASE3","title":"Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism","status":"TERMINATED","sponsor":"Shire","startDate":"2018-09-26","conditions":"Hypoparathyroidism","enrollment":22},{"nctId":"NCT02910466","phase":"PHASE4","title":"A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism","status":"COMPLETED","sponsor":"Shire","startDate":"2016-10-27","conditions":"Chronic Hypoparathyroidism, Hypoparathyroidism","enrollment":39},{"nctId":"NCT01268098","phase":"PHASE3","title":"Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)","status":"COMPLETED","sponsor":"Shire","startDate":"2011-02-09","conditions":"Hypoparathyroidism","enrollment":42},{"nctId":"NCT01455181","phase":"PHASE3","title":"A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary","status":"COMPLETED","sponsor":"Shire","startDate":"2011-08-19","conditions":"Hypoparathyroidism","enrollment":24},{"nctId":"NCT03150108","phase":"PHASE1","title":"Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects","status":"COMPLETED","sponsor":"Shire","startDate":"2017-05-16","conditions":"Hypoparathyroidism","enrollment":24},{"nctId":"NCT00732615","phase":"PHASE3","title":"Use of NPSP558 in the Treatment of Hypoparathyroidism","status":"COMPLETED","sponsor":"Shire","startDate":"2008-12-18","conditions":"Hypoparathyroidism","enrollment":124},{"nctId":"NCT02781844","phase":"PHASE1","title":"Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism","status":"COMPLETED","sponsor":"Shire","startDate":"2017-04-03","conditions":"Hypoparathyroidism","enrollment":34},{"nctId":"NCT01297309","phase":"PHASE3","title":"A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)","status":"COMPLETED","sponsor":"Shire","startDate":"2011-04-06","conditions":"Hypoparathyroidism","enrollment":51},{"nctId":"NCT00172133","phase":"PHASE3","title":"Open Label Extension Study of PREOS","status":"COMPLETED","sponsor":"Shire","startDate":"2001-10-16","conditions":"Osteoporosis","enrollment":1683},{"nctId":"NCT00856401","phase":"PHASE3","title":"ADD-ON Study to Existing Hypoparathyroidism Studies","status":"UNKNOWN","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2010-09","conditions":"Hypoparathyroidism","enrollment":62},{"nctId":"NCT00473265","phase":"PHASE2, PHASE3","title":"Bone Properties in Hypoparathyroidism: Effects of PTH","status":"COMPLETED","sponsor":"John P. Bilezikian","startDate":"2004-05","conditions":"Hypoparathyroidism","enrollment":68}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"rhPTH (1-84)","genericName":"rhPTH (1-84)","companyName":"Shire","companyId":"shire","modality":"Biologic","firstApprovalDate":"","aiSummary":"RhPTH (1-84) is a parathyroid hormone receptor agonist used to treat conditions such as hypoparathyroidism, chronic hypoparathyroidism, and osteoporosis. It is a protein-based drug that acts on the parathyroid hormone/parathyroid hormone-related peptide receptor.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}